in 2009 has demonstrated the siRNA-modified nano drug delivery platform downregulating expression of HIF1α in animal studies. Their findings revealed the potential of anti-HIF1α siRNA-based integrin targeted multifunctional nanocarrier knockdown of HIF-1α expression in human glioma xenograft mouse models. Here, HIF1A is linked to central nervous system cancer.